为促进药代动力学、药物递送、人工智能辅助药物研发等前沿方向的药学创新领域国际科研交流,苏州大学联合中国生物医药产业链创新转化联合体(CBIITA)药代动力 学专委会将于 2026 年 11 月 27-29 日在苏州举办2026苏州国际药学前沿论坛暨第二届国际临床ADMET预测研讨会。
本次研讨会将汇集来自韩国、美国、日本、泰国、英国、爱尔兰以及中国的知名专 家学者,覆盖学术界、产业界及监管机构,共同剖析行业面临的挑战,并探讨相应解决方案
演讲主题
新药上市申请(NDA)阶段的代谢物介导药物相互作用研究 / Metabolite-Mediated Drug-Drug Interaction Studies at the New Drug Application (NDA) Stage
Drug-drug interaction (DDI) evaluation at the New Drug Application (NDA) stage has evolved from a screening-level exercise into a comprehensive, mechanism-based scientific discipline. The finalization of ICH M12 at Step 4 (2024) has established international expectations for systematic DDI assessment encompassing both enzyme-mediated and transporter-mediated pathways.
This presentation examines three critical dimensions of modern NDA-stage DDI evaluation.
First, the increasing recognition of metabolites as active DDI precipitant — supported by multiple industry surveys demonstrating that the majority of major enzyme inhibitors possess circulating metabolites with inhibitory potency frequently exceeding that of the parent compound. Historical cases including terfenadine and gemfibrozil, together with recent approvals such as suzetrigine (Journavx) and idelalisib, illustrate the consequences of inadequate metabolite assessment.
Second, the quantitative framework for enzyme DDI — spanning CYP phenotyping via the metabolite generation method, reversible and time-dependent inhibition evaluation (IC50, Ki, Kinact/KI), and induction prediction through the Relative Induction Score (RIS) model with in vitro–in vivo extrapolation (IVIVE).
Third, the transporter dimension — covering the nine key transporters specified by ICH M12 (OATP1B1/1B3, BCRP, P-gp, OCT2, MATE1/2-K, OAT1, OAT3), R-value-based clinical risk assessment, and the emerging role of endogenous biomarkers such as coproporphyrin I (CP-I) for non-invasive OATP1B monitoring.
Case studies from recent FDA approvals (2024–2026), including the first approved PROTAC, vepdegestrant, are presented to demonstrate the practical application of this integrated framework. Future perspectives including cryo-EM structural biology of hepatic transporters and AI/ML-enhanced DDI prediction are also discussed.
加入订阅
获取药物代谢与药代动力学最新专业内容和信息